On 26 October 2018, Proxalutamide and Abiraterone joint Phase III Clinical Trial Researchers’ Conference was successfully held in Hyatt Regency Shanghai, marking the official start of the second Phase III clinical trial of Proxalutamide, innovative drug independently developed by Suzhou Kintor Pharmaceuticals (“Kintor”). 37 hospitals participated the conference.
Group photo of all experts in the conference
The clinical trial was led by Shanghai Changhai Hospital and Fudan University Affiliated Oncology Hospital, with Professor Sun Yinghao (孙颖浩) and Professor Ye Dingwei (叶定伟) being the joint Principal Investigators (PI). R&G PharmaStudies Co., Ltd. (诺思格医药) and Predicine, Inc (慧渡医疗) are the cooperation research organization and biomarker detection center respectively. The Researchers’ Conference was hosted by Kintor, and nearly 100 experts in the prostate cancer field and clinical sites investigators from 37 hospitals across the nation gathered together to contribute ideas on Pruformamide and Abiraterone joint Phase III clinical trial.
Dr. Tong Youzhi, Chairman& CEO of Kintor
Dr. Tong Youzhi (童友之), Chairman and CEO of Kintor, made an opening speech to introduce the clinical strategy of Phase III clinical trial of Proxalutamide as the first-line drug for metastatic Castration Resistant Prostate Cancer (mCRPC) and expressed gratitude to all the participants.
Dr. Sun Yinghao, Project PI, Academician of the Chinese Academy of Engineering, President of the Second Military Medical University, and Chairman of the Chinese Medical Association Urological Surgery, indicated on the conference that “Kintor’s Proxalutamide R&D project is rigorous. All organizations participating in the Phase III clinical trial should communicate from time to time in order to complete this project successfully. This clinical trial will provide valuable experience to innovative drug research. We should constantly explore reasonable solutions in the process of project development, so that the clinical trial can achieve both current expectations and broader expansion.”
Dr.Sun Yinghao, Principal Investigator of clinical trial
“It is very commendable for Kintor to launch a clinical trial with such a large sample in China especially when only multinational paratheatrical companies can conduct such trial previously.” said the PI of this clinical trial, Associate Dean of the Fudan University Affiliated Oncology Hospital, Chief Expert of the Multidisciplinary Collaborative Diagnosis and Treatment Center for Urinary Men’s Reproductive System Cancer, Professor Ye Dingwei.“Through previous clinical trials, we have seen the high value of Proxalutamide as an innovative drug. I hope that we can get a good experimental result for it to be used together with Abiraterone and finally become a star drug in the market.”
Dr.Ye Dingwei, joint Principal Investigator of clinical trial
In May 2018, the kick-off meeting of first Phase III clinical trial of Proxalutamide was successfully hosted by Kintor in Suzhou, which focus on Proxalutamide as a second-line treatment of mCRPC to meet the urgent needs of advanced patients. This aims to complete the clinical trial on Proxalutamide as a single drug.
The second Phase III clinical trial kicked-off in this conference on Proxalutamide tablet as a first-line treatment of mCRPC has been Kintor’s largest investment of resources in clinical development since its inception. It aims to expand the therapeutic response of advanced patients and overcome drug resistance with the combined usage of Abiraterone in order to provide the best treatment for mCRPC patients.